A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Busulfan (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Autologous stem cell therapy
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms BuMelMCRN001
- 20 Sep 2017 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 20 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.